Clinical Trials Logo

Non-ischemic Cardiomyopathy clinical trials

View clinical trials related to Non-ischemic Cardiomyopathy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03925324 Terminated - Clinical trials for Ischemic Heart Disease

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device

STEM-VAD
Start date: May 3, 2019
Phase: Phase 2
Study type: Interventional

A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.

NCT ID: NCT02346422 Terminated - Heart Failure Clinical Trials

A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to characterize the safety profile and preliminary activity of high-dose MYDICAR® in persons with advanced heart failure when added to their maximal and optimized therapy.

NCT ID: NCT01966887 Terminated - Clinical trials for Ischemic Cardiomyopathy

AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure

AGENT-HF
Start date: December 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effect of intracoronary SERCA2a Gene transfer on cardiac volumes and function using multimodality cardiac imaging.

NCT ID: NCT01935622 Terminated - Clinical trials for Non-ischemic Cardiomyopathy

Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

DOXY-HF
Start date: July 2012
Phase: Phase 2
Study type: Interventional

Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation. Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects. In this study we plan to determine the effects of Doxycycline in patients with stable heart failure and non-ischemic cardiomyopathy on peak of aerobic exercise capacity (peak V02) and ventilator efficiency measured with a cardiopulmonary test.